PI-Institute study: Weaknesses in the business and manufacturing processes as well as in the efficiency of production and quality management companies in the pharmaceutical and chemical industry have significant weaknesses in their business and production processes. Alarm clock (L) / Hurth, 03.05.2010 – companies in the pharmaceutical and chemical industry have significant weaknesses in their business and production processes. The efficiency of the production and the quality management of the companies in the process industry deficits mostly. On these findings, a study of the PI production intelligence comes Institute. It went the question of what critical needs IT support for this business enterprise in the future especially should focus on. Based on the results, a matrix of IT requirements was developed and determined the possible solutions of the integrative approach of production intelligence. The need for solutions that lead to sustainably lower process costs in it shows a clear dominance. This aspect is by no less than 74 Percent surveyed companies in the forefront of over 100 made.
They give a similar urgency the realization of a continuous process of integration. At its core is pointed out so that the process orientation in the pharmaceutical and chemical industry still far from a needs-based status is away”, rated Jeannette Ewen, Managing Director of the PI Institute, the results. Indeed, it is in practice, for example, a juxtaposition of business and production processes can be observed. The production area is largely encapsulated by the other business processes and proves to be a kind of black box”, it problematized. The disadvantage is not only that as a result value chains are interrupted, rather be detached and uncoordinated developed by the corporate goal, and implemented changes and improvements. So the potentials can be used in the business nor in the production processes sufficiently to improve performance”, refers to a variety of negative consequences Ewen an insufficient Process integration.